227 related articles for article (PubMed ID: 1702006)
41. An abnormal CD34+ myeloid/CD34+ lymphoid ratio at the end of chemotherapy predicts relapse in patients with acute myeloid leukemia.
Martínez A; San Miguel JF; Vidriales MB; Ciudad J; Caballero MD; López-Berges MC; Moro MJ; Calmuntia MJ; Ortega F; Orfao A
Cytometry; 1999 Apr; 38(2):70-5. PubMed ID: 10323219
[TBL] [Abstract][Full Text] [Related]
42. Clinical and hematological correlates of aberrant immunophenotypic profiles in adult and pediatric acute myeloid leukemia at presentation.
Sharma M; Varma N; Singh Sachdeva MU; Bose P; Varma S
J Cancer Res Ther; 2020; 16(1):105-109. PubMed ID: 32362618
[TBL] [Abstract][Full Text] [Related]
43. Prognostic value of immunophenotypic characteristics of blast cells in acute myeloid leukemia.
Lanza F; Rigolin GM; Moretti S; Latorraca A; Castoldi G
Leuk Lymphoma; 1994; 13 Suppl 1():81-5. PubMed ID: 7521238
[TBL] [Abstract][Full Text] [Related]
44. Concomitant chronic lymphocytic leukemia and acute myeloid leukemia with an uncommon immunophenotype.
Mateu R; Bellido M; Sureda A; González Y; Rubiol E; Aventin A; Nomdedéu J
Am J Hematol; 1997 Dec; 56(4):281-7. PubMed ID: 9395193
[TBL] [Abstract][Full Text] [Related]
45. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
[TBL] [Abstract][Full Text] [Related]
46. Normal karyotype acute myeloid leukemia with the CD7+ CD15+ CD34+ HLA-DR + immunophenotype is a clinically distinct entity with a favorable outcome.
Iriyama N; Asou N; Miyazaki Y; Yamaguchi S; Sato S; Sakura T; Maeda T; Handa H; Takahashi M; Ohtake S; Hatta Y; Sakamaki H; Honda S; Taki T; Taniwaki M; Miyawaki S; Ohnishi K; Kobayashi Y; Naoe T
Ann Hematol; 2014 Jun; 93(6):957-63. PubMed ID: 24441947
[TBL] [Abstract][Full Text] [Related]
47. NPM1-mutated acute myeloid leukemia of monocytic or myeloid origin exhibit distinct immunophenotypes.
Liu YR; Zhu HH; Ruan GR; Qin YZ; Shi HX; Lai YY; Chang Y; Wang YZ; Lu D; Hao L; Li JL; Li LD; Jiang B; Huang XJ
Leuk Res; 2013 Jul; 37(7):737-41. PubMed ID: 23601747
[TBL] [Abstract][Full Text] [Related]
48. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
[TBL] [Abstract][Full Text] [Related]
49. Expression of lymphoid-associated cell surface antigens by childhood acute myeloid leukemia cells lacks prognostic significance.
Smith FO; Lampkin BC; Versteeg C; Flowers DA; Dinndorf PA; Buckley JD; Woods WG; Hammond GD; Bernstein ID
Blood; 1992 May; 79(9):2415-22. PubMed ID: 1571553
[TBL] [Abstract][Full Text] [Related]
50. P-glycoprotein (P-170) and CD34 expression in adult acute myeloid leukemia (AML).
Lamy T; Goasguen JE; Mordelet E; Grulois I; Dauriac C; Drenou B; Chaperon J; Fauchet R; le Prise PY
Leukemia; 1994 Nov; 8(11):1879-83. PubMed ID: 7526090
[TBL] [Abstract][Full Text] [Related]
51. Immunophenotypic characteristics of acute leukaemia after myelodysplastic syndromes.
Lima M; Teixeira Mdos A; Morais S; Cunha M; Coutinho J; Pinho L; Ribeiro P; Justiça B
Sangre (Barc); 1995 Feb; 40(1):49-52. PubMed ID: 7716672
[TBL] [Abstract][Full Text] [Related]
52. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
Zeleznikova T; Stevulova L; Kovarikova A; Babusikova O
Neoplasma; 2007; 54(6):471-7. PubMed ID: 17949229
[TBL] [Abstract][Full Text] [Related]
53. Phenotypic characterization of normal and CML CD34-positive cells: only the most primitive CML progenitors include Ph-neg cells.
De Fabritiis P; Dowding C; Bungey J; Chase A; Angus G; Szydlo R; Goldman JM
Leuk Lymphoma; 1993 Sep; 11(1-2):51-61. PubMed ID: 7693107
[TBL] [Abstract][Full Text] [Related]
54. Incidence and prognostic relevance of CD34 expression in acute myeloblastic leukemia: analysis of 141 cases.
Raspadori D; Lauria F; Ventura MA; Rondelli D; Visani G; de Vivo A; Tura S
Leuk Res; 1997 Jul; 21(7):603-7. PubMed ID: 9301680
[TBL] [Abstract][Full Text] [Related]
55. Contrasting antigenic maturation patterns in M0-M2 versus M3 acute myeloid leukemias.
Lewis RE; Cruse JM; Webb RN; Sanders CM; Beason K
Exp Mol Pathol; 2007 Oct; 83(2):269-73. PubMed ID: 17603036
[TBL] [Abstract][Full Text] [Related]
56. Biological characteristics of CD7 positive acute myelogenous leukaemia.
Eto T; Akashi K; Harada M; Shibuya T; Takamatsu Y; Teshima T; Niho Y
Br J Haematol; 1992 Nov; 82(3):508-14. PubMed ID: 1283077
[TBL] [Abstract][Full Text] [Related]
57. [Immunophenotype and P-glycoprotein expression in CD7 positive adult acute myeloid leukemia].
Hua D; Li J; Xia X
Zhonghua Xue Ye Xue Za Zhi; 1999 Feb; 20(2):88-90. PubMed ID: 11601207
[TBL] [Abstract][Full Text] [Related]
58. [Immunophenotypic study of acute myeloid leukemia (AML): biological significance and prognostic implications].
Rigolin GM; Latorraca A; Moretti S; Previati R; Lanza F
Boll Soc Ital Biol Sper; 1993 May; 69(5):301-5. PubMed ID: 8129911
[TBL] [Abstract][Full Text] [Related]
59. Detection of minimal residual disease in acute myeloid leukemia.
Gerhartz HH; Schmetzer H
Leukemia; 1990 Jul; 4(7):508-16. PubMed ID: 1695705
[TBL] [Abstract][Full Text] [Related]
60. Acute biphenotypic leukaemia: immunophenotypic and cytogenetic analysis.
Hanson CA; Abaza M; Sheldon S; Ross CW; Schnitzer B; Stoolman LM
Br J Haematol; 1993 May; 84(1):49-60. PubMed ID: 7687860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
